Deals In Depth: October 2013
Executive Summary
Eli Lilly agreed to co-promote Pfizer’s anti-NGF tanezumab for $200 million up front plus $350 million in regulatory milestones; private equity firms Avista and Nordic are taking Swiss pharmaco Acino private in a $439 million deal. Both biopharma and device financing increased in October vs. the previous month thanks to strong showings from IPOs and secondary offerings.